Table 1 Demographics and clinical characteristics for patients treated with and without PORT before and after PSM
Demographic or clinical characteristic | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
No PORT (N = 2090) | PORT (N=1244) | P | No PORT (N = 744) | PORT (N = 744) | P | |
Age, years (range) | 65.5 (22–89) | 65.7 (28–93) | 0.581 | 66.4 (62–89) | 65.7 (28–90) | 0.692 |
Gender | ||||||
Male | 1026 (62.0%) | 629 (38.0%) | 0.411 | 355 (48.2%) | 381 (51.8%) | 0.178 |
Female | 1064 (63.4%) | 615 (36.6%) | 389 (51.7%) | 363 (48.3%) | ||
Race | ||||||
White | 1689 (62.8%) | 999 (37.2%) | 0.720 | 604 (49.9%) | 607 (50.1%) | 0.842 |
Nonwhite | 401 (62.1%) | 245 (37.9%) | 140 (50.5%) | 137 (49.5%) | ||
Marital status | ||||||
Married | 1185 (59.4%) | 810 (50.6%) | 0.000 | 465 (50.6%) | 454 (49.4%) | 0.557 |
others | 905 (67.6%) | 434 (32.4%) | 279 (49.0%) | 290 (51.0%) | ||
Insurance | ||||||
Insured | 1261 (61.7%) | 783 (38.3%) | 0.135 | 462 (49.5%) | 471 (50.5%) | 0.629 |
others | 829 (64.3%) | 461 (35.7%) | 282 (50.8%) | 273 (49.2%) | ||
Laterality | ||||||
Left | 976 (63.9%) | 552 (36.1%) | 0.192 | 317 (47.7%) | 347 (52.3%) | 0.118 |
Right | 1114 (61.7%) | 692 (38.3%) | 427 (51.8%) | 397 (48.2%) | ||
Location | ||||||
Upper lobe | 1229 (61.5%) | 768 (38.5%) | 0.084 | 436 (48.9%) | 455 (51.1%) | 0.587 |
Middle lobe | 89 (58.9%) | 62 (41.1%) | 36 (52.9%) | 32 (47.1%) | ||
Lower lobe | 772 (65.1%) | 414 (34.9%) | 272 (51.4%) | 257 (48.6%) | ||
Tumor size, cm (range) | 3.8 (0.1–19.0) | 3.7 (0.5–15) | 0.340 | 3.7 (0.1–15) | 3.8 (0.5–15) | 0.670 |
LN positive (range) | 3.4 (1–41) | 3.8 (1–30) | 0.000 | 3.4 (1–33) | 3.5 (1–24) | 0.062 |
LN examined (range) | 12.2 (1–90) | 11.6 (1–64) | 0.006 | 11.9 (1–68) | 12.0 (1–61) | 0.473 |
% of LN positive (range) | 35.4 (1.4–100) | 41.2 (1.7–100) | 0.000 | 35.5 (1.4–100) | 35.8 (1.7–100) | 0.380 |
Histology | ||||||
Adenocarcinoma | 1423 (61.5%) | 891 (38.5%) | 0.097 | 478 (48.1%) | 515 (51.9%) | 0.110 |
Squamous cell carcinoma | 505 (65.2%) | 270 (34.8%) | 204 (54.4%) | 171 (45.6%) | ||
Adenosquamous and large cell carcinoma | 162 (66.1%) | 83 (33.9%) | 62 (51.7%) | 58 (48.3%) | ||
Differentiation | ||||||
Well differentiated | 131 (72.4%) | 50 (27.6%) | 0.012 | 20 (40.8%) | 29 (59.2%) | 0.548 |
Moderately differentiated | 930 (61.5%) | 581 (38.5%) | 354 (51.1%) | 339 (48.9%) | ||
Poorly differentiated | 969 (62.2%) | 589 (37.8%) | 354 (49.7%) | 358 (50.3%) | ||
Undifferentiated | 60 (71.4%) | 24 (28.6%) | 16 (47.1%) | 18 (52.9%) | ||
Surgical procedure | ||||||
Sublobectomy | 145 (51.4%) | 137 (48.6%) | 0.000 | 50 (51.0%) | 48 (49.0%) | 0.972 |
Lobectomy | 1741 (62.9%) | 1026 (37.1%) | 643 (49.9%) | 646 (50.1%) | ||
Pneumonectomy | 204 (71.6%) | 81 (28.4%) | 51 (50.5%) | 50 (49.5%) | ||
T stage (sixth edition) | ||||||
T1 | 629 (61.3%) | 397 (38.7%) | 0.359 | 235 (50.6%) | 229 (49.4%) | 0.908 |
T2 | 1341 (63.6%) | 768 (36.4%) | 468 (49.8%) | 471 (50.2%) | ||
T3 | 120 (60.3%) | 79 (39.7%) | 41 (48.2%) | 44 (51.8%) | ||